The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2025The Role of the Transcriptome in PD: A Novel Approach to PD Therapeutics
Study Rationale: Families, caregivers, and individuals living with Parkinson’s disease are in need of new biomarkers and effective therapies. To date, most of the studies have focused on DNA and...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2025RNAi Therapeutics Targeting Stearoyl-CoA-Desaturase as a Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Previous research has found that a type of fat molecules, called unsaturated fatty acids, are important regulators of toxicity in brain cells caused by the protein alpha-synuclein – a...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of CNS-Specific mTOR Inhibition for Enhanced Autophagy and Alpha-synuclein Clearance in Parkinson’s Disease
Study Rationale: A major problem in Parkinson’s disease (PD) is the buildup of a protein called alpha-synuclein, which damages brain cells. One way to help clear this toxic protein is by activating a...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2025Determining PINK1 and PRKN Enzyme Activities In Vivo.
Study Rationale: In Parkinson’s disease, loss of nigral dopaminergic neurons leads to motor symptoms. PINK1 and PRKN are both proteins involved in mitochondrial quality control, which when carrying...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2025Treatment of APOE4-associated Cognitive Decline in Parkinson’s Disease by an Adeno-associated Virus Coding for the Combined APOE2 and APOE-Christchurch Variants
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2025Molecular Magnetic Resonance Imaging (mMRI) GlioScope: A Comprehensive Approach to Noninvasive Profiling of Neuroinflammation in Pre-clinical Models of Parkinson’s Disease.
Study Rationale: The biology of the spread of Parkinson’s disease (PD) is very complicated and not yet well understood. However, one of the key drivers has been identified as neuroinflammation and the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.